<DOC>
	<DOCNO>NCT01149122</DOCNO>
	<brief_summary>The purpose study determine whether Gemcitabine/Oxaliplatin ( GEMOX ) without Erlotinib ( Tarceva ) effective treatment unresectable , metastatic biliary tract carcinoma .</brief_summary>
	<brief_title>Gemcitabine/Oxaliplatin ( GEMOX ) With Without Erlotinib ( Tarceva ) Advanced Biliary Tract Carcinoma</brief_title>
	<detailed_description>This phase III study Gemcitabine/Oxaliplatin ( GEMOX ) without Erlotinib unresectable , metastatic biliary tract carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. age ≥ 18 2. histologically cytologically confirm adenocarcinoma biliary tract 3. unresectable metastatic 4 . ECOG performance status 0~2 5. measurable evaluable lesion per RECIST criterion 6. adequate marrow , hepatic , renal cardiac function 7. prior chemotherapy molecularly target therapy advance biliary carcinoma ( prior adjuvant chemotherapy allow administer ≥ 6 month study entry ) 8. provision sign write informed consent 1. severe comorbid illness and/or active infection 2. pregnant lactate woman 3. active CNS metastasis controllable radiotherapy corticosteroid 4. known history hypersensitivity study drug 5. prior exposure EGFR tyrosine kinase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>unresectable , metastatic biliary tract carcinoma</keyword>
	<keyword>Gemcitabine/Oxaliplatin ( GEMOX )</keyword>
	<keyword>Erlotinib</keyword>
</DOC>